Article open access publication

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

The Lancet Oncology, Elsevier, ISSN 1470-2045

Volume 19, 6, 2018

DOI:10.1016/s1470-2045(18)30192-x, Dimensions: pub.1103814600, PMID: 29735299,

Affiliations

Organisations

  1. (1) University Medical Centre Mannheim, grid.411778.c
  2. (2) Skåne University Hospital, grid.411843.b
  3. (3) Centre Hospitalier Universitaire de Poitiers, grid.411162.1
  4. (4) University Hospital of North Norway, grid.412244.5
  5. (5) St Olav's University Hospital, grid.52522.32
  6. (6) Portuguese Oncology Institute, grid.418711.a
  7. (7) VU University Medical Center, grid.16872.3a
  8. (8) University Hospital Brno, grid.412554.3
  9. (9) Helsinki University Central Hospital, grid.15485.3d
  10. (10) University of Helsinki, grid.7737.4
  11. (11) First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece
  12. (12) Uppsala University Hospital, grid.412354.5
  13. (13) Hospital Universitario 12 de Octubre, Centro Nacional de Investigaciones OncolÓgicas, Centro de Investigación Biomédica en Red de Cáncer, Universidad Complutense de Madrid, Madrid, Spain
  14. (14) Centre Hospitalier de Versailles, grid.418080.5
  15. (15) Odense University Hospital, grid.7143.1, Southern Denmark Region
  16. (16) Lund University, grid.4514.4
  17. (17) Turku University Hospital, grid.410552.7
  18. (18) Institute of Haematology and Blood Transfusion, grid.419035.a
  19. (19) Institute for Hematology and Oncology, Mannheim, Germany
  20. (20) University of Clermont Auvergne, grid.494717.8
  21. (21) Jena University Hospital, grid.275559.9
  22. (22) Ludwig Maximilian University of Munich, grid.5252.0
  23. (23) University of Bordeaux, grid.412041.2

Description

BACKGROUND: Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a prerequisite for TKI therapy discontinuation. We aimed to define precise conditions for stopping treatment. METHODS: In this prospective, non-randomised trial, we enrolled patients with chronic myeloid leukaemia at 61 European centres in 11 countries. Eligible patients had chronic-phase chronic myeloid leukaemia, had received any TKI for at least 3 years (without treatment failure according to European LeukemiaNet [ELN] recommendations), and had a confirmed deep molecular response for at least 1 year. The primary endpoint was molecular relapse-free survival, defined by loss of major molecular response (MMR; >0·1% BCR-ABL1 on the International Scale) and assessed in all patients with at least one molecular result. Secondary endpoints were a prognostic analysis of factors affecting maintenance of MMR at 6 months in learning and validation samples and the cost impact of stopping TKI therapy. We considered loss of haematological response, progress to accelerated-phase chronic myeloid leukaemia, or blast crisis as serious adverse events. This study presents the results of the prespecified interim analysis, which was done after the 6-month molecular relapse-free survival status was known for 200 patients. The study is ongoing and is registered with ClinicalTrials.gov, number NCT01596114. FINDINGS: Between May 30, 2012, and Dec 3, 2014, we assessed 868 patients with chronic myeloid leukaemia for eligibility, of whom 758 were enrolled. Median follow-up of the 755 patients evaluable for molecular response was 27 months (IQR 21-34). Molecular relapse-free survival for these patients was 61% (95% CI 57-64) at 6 months and 50% (46-54) at 24 months. Of these 755 patients, 371 (49%) lost MMR after TKI discontinuation, four (1%) died while in MMR for reasons unrelated to chronic myeloid leukaemia (myocardial infarction, lung cancer, renal cancer, and heart failure), and 13 (2%) restarted TKI therapy while in MMR. A further six (1%) patients died in chronic-phase chronic myeloid leukaemia after loss of MMR and re-initiation of TKI therapy for reasons unrelated to chronic myeloid leukaemia, and two (<1%) patients lost MMR despite restarting TKI therapy. In the prognostic analysis in 405 patients who received imatinib as first-line treatment (learning sample), longer treatment duration (odds ratio [OR] per year 1·14 [95% CI 1·05-1·23]; p=0·0010) and longer deep molecular response durations (1·13 [1·04-1·23]; p=0·0032) were associated with increasing probability of MMR maintenance at 6 months. The OR for deep molecular response duration was replicated in the validation sample consisting of 171 patients treated with any TKI as first-line treatment, although the association was not significant (1·13 [0·98-1·29]; p=0·08). TKI discontinuation was associated with substantial cost savings (an estimated €22 million). No serious adverse events were reported. INTERPRETATION: Patients with chronic myeloid leukaemia who have achieved deep molecular responses have good molecular relapse-free survival. Such patients should be considered for TKI discontinuation, particularly those who have been in deep molecular response for a long time. Stopping treatment could spare patients from treatment-induced side-effects and reduce health expenditure. FUNDING: ELN Foundation and France National Cancer Institute.

Funders

Research Categories

Main Subject Area

Fields of Research

Links & Metrics

NORA University Profiles

University of Southern Denmark

Dimensions Citation Indicators

Times Cited: 153

Field Citation Ratio (FCR): 88.11

Relative Citation ratio (RCR): 16.47

Open Access Info

Green, Published